8月31日 - ** 制药公司BioMarin Pharmaceutical（BMRN.O）的股价在盘前交易中上涨5.9%，至68.48美元
** BioMarin与Ascendis Pharma（ASND.O）就Ascendis的生长障碍药物Yuviwel所涉的所有专利纠纷达成和解（(link)）
** Ascendis将从该药物首次商业销售起，就Yuviwel在美国的销售额向BioMarin支付20%的专利使用费
** Ascendis 还同意，在 2030 年 5 月之前，就 Yuviwel 在欧盟、巴西和韩国的销售额向 BioMarin 支付 18% 的专利使用费
** Yuviwel是Ascendis公司开发的一种每周注射一次的治疗药物，适用于2岁及以上患有软骨发育不全（最常见的侏儒症类型）的儿童，该药已于2月获得美国FDA的加速批准 (link)
** 该法律纠纷始于2025年，当时BioMarin向美国国际贸易委员会（ITC）提起申诉，指控Ascendis的药物侵犯了其专利
** 截至上一交易日收盘，BMRN今年以来累计上涨8.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.